J&J Talc Settlement: Lawmakers Keep Stake While Company Pays $5.5B

What Happened

Johnson & Johnson (JNJ:US) announced on Monday, July 28, 2026 that it will pay $5.5 billion to settle roughly 69,000-76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement closes out 99.75% of remaining talc litigation after 15 years of legal battles.

According to Capitol Trades data, lawmakers have held a running financial position in J&J throughout this period — with 161 trades logged from 37 politicians across the past few years. The company denies that talc products cause cancer and pulled its product from North American shelves in 2020.

The deal requires approval from 95% of claimants and a federal judge before finalization, and covers only existing claims. Despite the litigation cloud, J&J shares have been up 60% over the past year.

Key Congressional Trades

Capitol Trades logs 113 separate filings totaling $2.81 million in disclosed volume from lawmakers trading J&J stock. Notable traders include:

• Thomas Kean Jr. (home state hosts J&J headquarters) has been a steady seller
• Lloyd Doggett kept buying since early 2025
• George Whitesides and Kevin Hern each disclosed sells in the $100K-$250K range
• Ro Khanna is the most frequent trader, buying and selling repeatedly from 2025 to July 2026

Important Context: STOCK Act Filings Lag Actual Trades

STOCK Act filings typically lag actual trades by 20-40 days and report ranges rather than exact amounts. This means the disclosed volumes represent what was filed with Congress, not necessarily the precise dollar amounts of individual transactions. The law requires members of Congress to disclose stock trades within a set timeframe, but these disclosures come after the fact.

Why It Matters

This settlement represents one of the largest corporate litigation payouts in recent years for a consumer products company. The $5.5 billion figure comes with significant caveats: it covers only existing claims and requires supermajority claimant approval plus judicial sign-off before closing.

The presence of lawmakers trading J&J stock while legislation or investigations involving the company could arise creates an ongoing transparency question under the STOCK Act. Capitol Trades data shows 37 different politicians have traded J&J, with filings totaling nearly $3 million in disclosed volume over multiple years.

The settlement announcement comes after J&J pulled talc products from North American shelves in 2020, citing concerns about potential cancer risks. The company has maintained that its talc products do not cause cancer throughout the litigation period.

What to Watch

• Final settlement approval: The deal needs 95% claimant approval and federal judge sign-off before finalization
• Additional claims: The settlement only covers existing claims; new lawsuits could emerge
• Further congressional trading: Lawmakers continue to trade J&J, with filings lagging actual trades by 20-40 days
• Stock performance: J&J shares up 60% despite litigation cloud

By the numbers

Source snapshot

This article reports on public disclosures and mandated filings. All figures are from official sources including Capitol Trades. This is informational reporting of public disclosures, not financial advice.

Sources: - https://www.capitoltrades.com/articles/j-j-pays-5-5b-settling-cancer-claims-lawmakers-keep-stake-2026-07-28 - https://www.capitoltrades.com/